Univariate analysis of survival predictors after referral to phase 1 clinic in patients with wtBRAF advanced cancer.

1Royal Marsden Hospital (RMH) 13 prognostic score is determined as follows: 0 points, normal lactate dehydrogenase (LDH), albumin ≥3.5 g/dL, a ≤2 metastatic sites; 1 point- LDH>upper limit of normal, albumin 2 metastatic sites. Patients with 0–1 points had a good RMH score, and patients with 2–3 points had a poor RMH score.2Among the 149 patients with wtBRAF, 22 patients were treated with RAF/MEK targeting agents, 64 patients were treated with non RAF/MEK targeting agents, 18 patients never been enrolled in phase 1 trial after referral and 45 patients from melanoma department who were not referred to the phase 1 department the time of the analysis.3Patients who never had a restaging at the last follow-up or who never started on a phase 1 trial were excluded in the univariate analysis (N = 24).4Only patients who were referred to the phase 1 clinic were considered in this analysis (Overall survival from time of referral to the phase 1 clinic).